eisai has announced the launch of a new stateoftheart packaging facility at its emea knowledge centre in hatfield.the new twostorey 2,900 sq m factory expands the current site by nearly 40 percent and will lead to a ten percent increase in the location&39s 500strong workforce. it will be used to handle the packaging of the investigational advanced thyroid cancer treatment lenvatinib.this represents a foreign direct investment of more than eight million pounds into the uk, thus reinforcing eisai&39s position as the country&39s largest japanese pharmaceutical investor. lenvatinib will be packaged exclusively at hatfield and eventually exported to almost 200 countries.although it is yet to be approved, the therapy has been granted orphan drug designation and accepted for accelerated regulatory review in europe.mr haruo naito, chief executive officer of eisai, said "the uk is an ideal location for advanced manufacturing. we are committed to the life sciences industry in this country and it will continue to play a pivotal role in our commercial growth strategy."lenvatinib has demonstrated significant progressionfree survival benefits when compared to placebo in phase iii clinical trials.other news stories from 26112014eisai launches new packaging facility in hatfieldnovartis&39 signifor approved in europe as acromegaly treatmentastrazeneca and amgen report positive psoriasis drug trial datarelated newseisai launches new packaging facility in hatfieldeisai to present cancer drug data at esmo 2014eisai applies for new eu and us approval for fycompaeisai applies for regulatory approval of new thyroid cancer drugeisai&39s halaven approved for earlier usage against breast cancer in euread more in the zenopa news archivehow this news is generatedsource httpwww.zenopa.comnews801762397eisailaunchesnewpackagingfacilityinhatfield
